Skip to content
DataLookout
Start free
Menu

VAST-ANCT05139849

VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 2 years later, enrollment reduced 39%.

See at-risk trials from Tiohundra AB

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 1276 → 784 participants Show 7 more changesShow less
    • Primary completion pushed from Jan 31, 2027 to Jan 31, 2029
    • Start date: Nov 17, 2021 to Oct 12, 2026
    • Eligibility criteria expanded, about 9 words
    • Study completion pushed from Apr 30, 2027 to Jun 30, 2029
    • Interventions modified
    • Study description expanded, about 32 words
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Survival at 30 days
Timeframe: Survival at 30 days

Arms and interventions

InterventionActive comparator

Adrenaline, vasopressin and steroids arm (intervention) 1. At randomization 1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR. 1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR 2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 5 days.

ControlNo intervention

Standard care in cardiac arrest

Drugs: Vasopressin; Methylprednisolone; Hydrocortisone

Sites

2 sites in 1 country